Shi Rui, Braïk Rayan, Monnet Xavier, Gu Wan-Jie, Ospina-Tascon Gustavo, Permpikul Chairat, Djebbour Maxime, Soumare Alice, Agaleridis Vincent, Lai Christopher
Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-Sen University, The Emergency and Critical Care Clinical Research Center of Guangdong Province, Guangzhou, Guangdong, China.
AP-HP, Service de Médecine Intensive-Réanimation, Hôpital de Bicêtre, DMU 4 CORREVE, IHU PROMETHEUS, FHU SEPSIS, CARMAS, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Crit Care. 2025 May 6;29(1):182. doi: 10.1186/s13054-025-05400-z.
The optimal timing for initiating norepinephrine in septic shock is debated. This updated systematic review and meta-analysis aimed to evaluate the impact of early versus delayed norepinephrine initiation on mortality and clinical outcomes in adults with septic shock.
A systematic search in Pubmed, EMbase and the Cochrane Library to identify eligible randomized controlled trials, propensity score matching (PSM) and observational studies that compare early norepinephrine initiation with non-early norepinephrine initiation in patients with acute circulatory failure. The primary outcome was mortality in intensive care unit. Secondary outcomes included intensive care unit length of stay, fluid volume received at 6 h, norepinephrine dose, mechanical ventilation-free days, renal replacement therapy free days, and time to achieve a targeted mean arterial pressure (MAP). Meta-analysis and subgroup analysis were conducted to calculate odds ratio (OR) or mean difference with 95% confidence interval (95%CI) using random-effect model. Trial sequential analysis was conducted to evaluate the conclusiveness of evidence.
Ten studies (two RCT, three PSM and five observational studies) involving 4767 patients were included. Early norepinephrine significantly reduced mortality in RCT (OR 0.49, 95%CI 0.25-0.96; I = 45%, p = 0.04), pooled RCT and PSM (OR 0.65, 95%CI 0.42-0.99; I = 74%, p = 0.05), and observational studies (OR 0.71, 95%CI 0.54-0.94; I = 66%). The trial sequential analysis indicated more data are needed. Subgroup analyses showed reduced mortality with early norepinephrine when lactate was ≤ 3mmol/L and administered within 1 h. Secondary outcomes showed a reduced fluid volume at 6h (RCT + PSM: mean difference -502 mL, 95%CI -899 to -106; I = 91%, p = 0.01), faster MAP target achievement (RCT + PSM: mean difference -1.30h, 95%CI -1.75 to -0.85; I = 0%, p < 0.01), more mechanical ventilation-free days (RCT + PSM: mean difference 3.99 days, 95%CI 2.42-5.57; I = 32%, p < 0.01) and smaller cumulative norepinephrine dose (Observational: mean difference -3.44 mcg/kg, 95%CI -6.13 to -0.76; I = 0%, p = 0.01) in the early initiation group compare to the non-early initiation group.
Early norepinephrine introduction in septic shock is associated with reduced mortality, decreased fluid volume administered at 6 h, faster time to achieve MAP target and more mechanical ventilation-free days. However, the trial sequential analysis indicates that further RCT are still needed to confirm these findings.
脓毒性休克中开始使用去甲肾上腺素的最佳时机存在争议。这项更新的系统评价和荟萃分析旨在评估早期与延迟使用去甲肾上腺素对脓毒性休克成年患者死亡率和临床结局的影响。
在PubMed、EMbase和Cochrane图书馆进行系统检索,以识别符合条件的随机对照试验、倾向评分匹配(PSM)和观察性研究,这些研究比较了急性循环衰竭患者中早期与非早期使用去甲肾上腺素的情况。主要结局是重症监护病房的死亡率。次要结局包括重症监护病房住院时间、6小时时接受的液体量、去甲肾上腺素剂量、无机械通气天数、无肾脏替代治疗天数以及达到目标平均动脉压(MAP)的时间。使用随机效应模型进行荟萃分析和亚组分析,以计算比值比(OR)或平均差以及95%置信区间(95%CI)。进行试验序贯分析以评估证据的确定性。
纳入了10项研究(2项随机对照试验、3项倾向评分匹配研究和5项观察性研究),涉及4767例患者。在随机对照试验中,早期使用去甲肾上腺素显著降低了死亡率(OR 0.49,95%CI 0.25 - 0.96;I² = 45%,p = 0.04),在汇总的随机对照试验和倾向评分匹配研究中(OR 0.65,95%CI 0.42 - 0.99;I² = 74%,p = 0.05),以及在观察性研究中(OR 0.71,95%CI 0.54 - 0.94;I² = 66%)。试验序贯分析表明还需要更多数据。亚组分析显示,当乳酸≤3mmol/L且在1小时内给药时,早期使用去甲肾上腺素可降低死亡率。次要结局显示,与非早期起始组相比,早期起始组在6小时时液体量减少(随机对照试验 + 倾向评分匹配:平均差 -502 mL,95%CI -899至 -106;I² = 91%,p = 0.01),达到MAP目标的时间更快(随机对照试验 + 倾向评分匹配:平均差 -1.30小时,95%CI -1.75至 -0.85;I² = 0%,p < 0.01),无机械通气天数更多(随机对照试验 +倾向评分匹配:平均差3.99天,95%CI 2.42 - 5.57;I² = 32%,p < 0.01),累积去甲肾上腺素剂量更小(观察性研究:平均差 -3.44 mcg/kg,95%CI -6.13至 -0.76;I² = 0%,p = 0.01)。
脓毒性休克中早期引入去甲肾上腺素与死亡率降低、6小时时给予的液体量减少、更快达到MAP目标以及更多无机械通气天数相关。然而,试验序贯分析表明仍需要进一步的随机对照试验来证实这些发现。